SecBot SecBot

ALXO drug pipeline

ALX ONCOLOGY HOLDINGS INC · 2 rated drugs
$1.06
+3.9% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketAt least 5-7 years if successful (currently in Phase 1 dose-escalation; typical ADC development timelines from Phase 1 to approval span 5-8 years)

ALX2004 Updated Jun 30

What to watch

Investors should watch for the Phase 1 safety data readout in 2H 2026, which will be the first clinical data for this program. Positive results could unlock a $10M contingent tranche from HSVC's $50M credit facility. The data will also validate ALXO's internal ADC platform and inform whether the drug can differentiate in a competitive EGFR-targeted ADC landscape where MRG003 (becotatug vedotin) was already approved in China in November 2025.

Bull case
  • Differentiated mechanism: ALX2004 uses a proprietary topoisomerase I inhibitor payload with a linker designed for improved stability and reduced skin toxicity, potentially overcoming the tolerability limitations that plagued earlier EGFR-targeted ADCs like depatux-m (AbbVie, which failed Phase III).
  • Strong preclinical data presented at AACR-NCI-EORTC 2025 showed superior bystander killing effect compared to deruxtecan-based ADCs, suggesting potential for activity in heterogeneous tumors.
  • Clear early safety signal: Dose escalation has progressed through 1 mg/kg and 2 mg/kg cohorts with no dose-limiting toxicities reported, and the 4 mg/kg cohort is enrolling, supporting the differentiated tolerability thesis.
Bear case
  • Very early stage: ALX2004 is in Phase 1 dose-escalation with no efficacy data yet, the vast majority of Phase 1 oncology assets never reach approval. Clinical data is still ~3-6 months away.
  • Crowded competitive landscape: The first EGFR-targeted ADC (MRG003/becotatug vedotin by Lepu Biopharma) was already approved in China in November 2025. There are 25+ companies and 30+ drugs in the EGFR NSCLC pipeline alone. Enhertu (HER2 ADC) has set a high bar for ADC expectations.
  • Pipeline lagging behind lead asset: ALX2004 is ALXO's second program; evorpacept (CD47 blocker) is the primary value driver. ALX2004 alone is unlikely to move the stock dramatically given the company's broader pipeline focus.
◆ mixed
Impact
PhasePhase 2/3 (ASPEN-06 in HER2+ gastric cancer); Phase 2 (ASPEN-09-Breast in HER2+ breast cancer)
Time to marketUnknown; earliest potential FDA submission would likely be 2027-2028, assuming Phase 3 data from ASPEN-06 supports a BLA filing.

evorpacept Updated Jun 30

What to watch

Watch for ASPEN-06 Phase 3 enrollment completion and any FDA interaction updates, the company earned Fast Track designation for HER2+ gastric cancer in Jan 2025 and plans to discuss the path forward with FDA. The ALX2004 safety readout in 2H 2026 could move shares indirectly by validating the pipeline beyond evorpacept. The stock has strong institutional backing (RA Capital, Blackstone, Driehaus) but is still clinical-stage with no revenue and the CD47 class carries a high failure rate.

Bull case
  • Evorpacept's inactive Fc domain is structurally differentiated from first-gen CD47 antibodies (magrolimab, lemzoparlimab), designed to avoid the anemia-related toxicities that forced Gilead into a partial clinical hold and ended AbbVie's I-Mab collaboration, if successful, evorpacept could dominate the CD47 class.
  • Phase 2 ASPEN-06 data showed clear benefit in HER2+ gastric cancer, earning FDA Fast Track designation (Jan 2025). Exploratory biomarker data identifying CD47 expression as a predictor of response (65% ORR in CD47-high cohort) provides a precision medicine angle that could increase Phase 3 success odds.
  • Institutional accumulation is massive: RA Capital opened a $26M position, Blackstone added $11.7M, Driehaus doubled to $11.5M, and Marshall Wace increased 14,144%, all in Q1 2026, suggesting sophisticated investors see value.
Bear case
  • The CD47 inhibitor class has been a graveyard, Gilead's magrolimab (acquired for $4.9B) hit partial clinical holds, and AbbVie terminated its I-Mab collaboration after Phase 2 failures. Evorpacept is differentiated but still in the same mechanism class.
  • No near-term binary catalyst: the next hard evorpacept data readout (ASPEN-09-Breast) is mid-2027, over 12 months out. No PDUFA date exists. The stock lacks a share-price catalyst in the coming year.
  • The stock was heavily diluted in Jan 2026, a $150M offering priced at roughly $1.50-1.70/share, increasing shares outstanding significantly. The stock is down ~90% from its 2020 highs.